FrancophonIA/ELRC3.0 huggingface dataset:
English: • [EMA/MB/805742/2011] Preliminary work programme.
Estonian: • [EMA/MB/805742/2011] Esialgne tööprogramm
English: • [EMA/807799/2010] Annual report 2010 of the Agency's Internal Audit.
Estonian: • [EMA/807799/2010] EMA siseauditi üksuse 2010. aasta aruanne
English: • [EMA/MB/105462/2011] Outcome of written procedures during the period from 17 October 2010 to
Estonian: • [EMA/MB/105462/2011] 17. oktoobrist 2010 24. novembrini 2010 toimunud kirjalike menetluste tulemused
English: Revision of 'Charter of tasks and responsibilities of the Agency's accounting officer'
Estonian: EMA peaarvepidaja ülesannete ja kohustuste harta muutmine
English: • [EMA/786515/2010] Annual report 2010 of the Agency's Audit Advisory Committee.
Estonian: • [EMA/786515/2010] EMA auditi nõuandekomitee 2010. aasta aruanne
English: • The Mediator case (a stress test was conducted in the context of the new pharmacovigilance legislation).
Estonian: • benfluoreksi sisaldavate ravimite juhtum (Mediatori juhtum; kontrolliti uute ravimiohutuse järelevalve õigusaktide süsteemi koormustaluvust);
English: Mary G. Baker (morning session) Mike O'Donovan
Estonian: Mary G. Baker (koosoleku ennelõunane pool)
English: [EMA/MB/80540/2011] The Management Board adopted the revised charter of the accounting officer, which clarifies the accounting officer's obligations and responsibilities in line with the Financial Regulation.
Estonian: [EMA/MB/80540/2011] Haldusnõukogu võttis vastu peaarvepidaja harta muudetud versiooni, milles selgitatakse finantsmäärusele vastavaid peaarvepidaja kohustusi ja ülesandeid.
English: • outcome and recommendations from the Agency's evaluation and the stakeholder conference
Estonian: • EMA hindamise ja sidusrühmade konverentsi tulemused ja soovitused (Ernst & Youngi aruanne),
English: Audit reports
Estonian: Auditiaruanded
English: Amendments to the Management Board implementing rules on the Agency's fees
Estonian: EMA lõive käsitlevate haldusnõukogu rakenduseeskirjade muudatused
English: [EMA/MB/146523/2011] The Management Board noted the report on performance of national competent authorities with respect to a subset of KPIs, which had been agreed by the Board in June 2010.
Estonian: [EMA/MB/146523/2011] Haldusnõukogu võttis teadmiseks riikide pädevate asutuste tegevuse aruande , mis koostati tulemuslikkuse mitme põhinäitaja alusel, mille haldusnõukogu leppis kokku 2010. aasta juunis.
English: • [EMA/634206/2010] Minutes from the latest Management Board Telematics Committee meeting
Estonian: • [EMA/634206/2010] Haldusnõukogu telemaatikakomitee viimase koosoleku (2. november 2010)
English: EMA/MB/232704/2011 Management Board
Estonian: EMA/MB/728584/2011 Haldusnõukogu
English: Representative of healthcare professionals' organisations
Estonian: Tervishoiutöötajate ühingute esindaja
English: [EMA/MB/757388/2011] The Board adopted the amendments to the implementing rules on the Agency's fees.
Estonian: [EMA/MB/757388/2011] Haldusnõukogu võttis vastu EMA lõivude rakenduseeskirjade muudatused.
English: Report on the performance of the Agency's scientific procedures: key performance indicators (KPIs) for medicinal products for human and veterinary use
Estonian: EMA teaduslike menetluste tulemuslikkuse aruanneinim- ja veterinaarravimite tulemuslikkuse põhinäitajad
English: Mediator
Estonian: Mediatori juhtum
English: • No 03/2011 - the appointment of Zanda AUCE as CVMP member, proposed by Latvia, finalised on
Estonian: • nr 03/2011 - Zanda AUCE nimetamine veterinaarravimite komitee liikmeks Läti ettepanekul, menetlus valmis 4. veebruaril 2011;
English: Minutes of the 70th meeting of the Management Board
Estonian: Haldusnõukogu 70. koosoleku protokoll
English: Representative of veterinarians' organisations
Estonian: Veterinaariaühingute esindaja
English: • No 04/2011 - the appointment of Lyubina TODOROVA as CHMP alternate, proposed by Bulgaria,
Estonian: • nr 04/2011 - Lyubina TODOROVA nimetamine inimravimite komitee asendusliikmeks Bulgaaria ettepanekul, menetlus valmis 22. veebruaril 2011;
English: [EMA/MB/105478/2011] The Board adopted the revised consultation procedure and the revised CV template.
Estonian: [EMA/MB/105478/2011] Haldusnõukogu võttis vastu muudetud konsultatsioonimenetluse ja elulookirjelduse muudetud näidise.
English: • No 33/2010 - the appointment of Dalibor VALÍK as CHMP member, proposed by the Czech
Estonian: • nr 33/2010 - Dalibor VALÍKi nimetamine inimravimite komitee liikmeks Tšehhi Vabariigi ettepanekul, menetlus valmis 3. jaanuaril 2011;
English: • No 32/2010 - the appointment of Dana Gabriela MARIN as CHMP alternate, proposed by Romania,
Estonian: • nr 32/2010 - Dana Gabriela MARINi nimetamine inimravimite komitee asendusliikmeks Rumeenia ettepanekul, menetlus valmis 20. detsembril 2010;
English: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXX
Estonian: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
English: Other business
Estonian: Muud küsimused
English: • The enquiry by MEPs into off-label use of medicines in the EU (the MEPs' letters will be included on the April HMA agenda).
Estonian: (Euroopa Parlamendi liikmete kirjad lisatakse ravimiametite juhtide aprilli koosoleku päevakorrale).
English: (Ernst & Young report), presented by Nerimantas Steikūnas, of the EMA;
Estonian: ettekande tegi Nerimantas Steikūnas (EMA);
English: • No 02/2011 - the appointment of Miloslav SALAVEC as CHMP alternate, proposed by the Czech
Estonian: • nr 02/2011 - Miloslav SALAVECi nimetamine inimravimite komitee asendusliikmeks Tšehhi Vabariigi ettepanekul, menetlus valmis 4. veebruaril 2011;
English: In case the review will be completed later than the implementation work is due, the Agency requested the European Commission to provide for additional financial resources in the interim period.
Estonian: EMA palus vaheperioodiks Euroopa Komisjonilt täiendavaid rahalisi vahendeid, juhuks kui läbivaatamine lõpetatakse pärast rakendamistegevuse tähtaega.
English: The Board also noted the high level of activity in the area of variations.
Estonian: Samuti täheldas haldusnõukogu müügilubade sagedat muutumist.
English: • Preparation for the revision of the Fee Regulation, which will be carried out in two steps: first,
Estonian: • lõivude määruse läbivaatamise ettevalmistamine, mis toimub kahes etapis − kõigepealt muudetakse lõivude määrust nii, et EMA saaks võtta lõive ravimiohutuse järelevalve eest (seoses selle küsimuse kiireloomulisusega), millele järgneb kohe kogu lõivude määruse põhjalik läbivaatamine;
English: 4 February 2011.
Estonian: märts 2011
English: • No 01/2011 - the appointment of Helen JUKES as CVMP member, proposed by the United
Estonian: • nr 01/2011 - Helen JUKESi nimetamine veterinaarravimite komitee liikmeks Ühendkuningriigi ettepanekul, menetlus valmis 11. jaanuaril 2011;
English: A formal letter can be issued to the IMI board as part of the process to improve prospects of obtaining funding.
Estonian: Rahastamisväljavaadete parandamiseks võib innovatiivsete ravimite algatuse ühisettevõtte juhatusele saata ametliku kirja.
English: For the other three patients, this information was lacking.
Estonian: Ülejäänud 3 patsiendi kohta see teave puudus.
English: Methadone is a synthetic opioid.
Estonian: Metadoon on sünteetiline opioid.
English: However, available data do not demonstrate the effectiveness of povidone in mitigating this risk.
Estonian: Olemasolevad andmed aga ei näita povidooni efektiivsust selle riski leevendamisel.
English: This leads to ‘povidone storage disease' that may cause serious harm.
Estonian: See põhjustab n-ö povidooni ladestumise haiguse, mis võib tekitada suurt kahju.
English: Most of the patients were currently or previously included in OST programs.
Estonian: Enamik patsiente osaleb praegu või osales varem opioid-asendusravi programmides.
English: • The PRAC considered the proportionate response to the evidence of harm.
Estonian: • Riskihindamiskomitee arutas proportsionaalset reaktsiooni kahjude andmetele.
English: Additional warnings in the label were further considered, but a direct information to the patients is challenging and according to the experts, such measures are unlikely to further minimise the risk of injection.
Estonian: Kaaluti ka täiendavate hoiatuste lisamist märgistusele, kuid otsese teabe andmine patsientidele on keerukas küsimus ja ekspertide sõnul on ebatõenäoline, et sellised meetmed minimeerivad süstimisriski.
English: Fourteen (14) cases of renal failure were reported.
Estonian: Teatati 14 neerupuudulikkuse juhtumit.
English: The condition for lifting the suspension of these marketing authorisations is set out in Annex IV.
Estonian: Müügilubade peatamise tühistamise tingimused on IV lisas.
English: For 12 of the 15 patients, evidence that they had been prescribed or used methadone (urine sample or patient's statement) was available.
Estonian: 12 patsiendi korral 15st oli tõendatud, et neile oli määratud või nad olid kasutanud metadooni (uriiniproov või patsiendi kinnitus).
English: The review of oral methadone medicines containing povidone started on 10 April 2014 under Article 107i of Directive 2001/83/EC.
Estonian: Povidooni sisaldavate suukaudsete metadoonravimite andmete läbivaatamine algas 10. aprillil 2014 direktiivi 2001/83/EÜ artikli 107i alusel.
English: The product information of this methadone oral solution already contains clear advice that it should not be injected.
Estonian: Kõnealuse suukaudse metadoonilahuse ravimiteave juba sisaldab selget nõuannet, et ravimit ei tohi süstida.
English: Should this oral solution be repeatedly injected, povidone would be permanently retained and accumulate within organs and tissues, leading to potential serious harm.
Estonian: Kui seda suukaudset lahust süstitakse korduvalt, jääb povidoon püsivalt organismi ja koguneks elunditesse ja kudedesse, tekitades potentsiaalselt suurt kahju.
English: The overall effectiveness of methadone maintenance treatment is established in the literature and has been reviewed in several articles.
Estonian: Metadoon-säilitusravi üldine efektiivsus on kirjanduses hästi tõestatud ja sellest on mitu ülevaateartiklit.
English: Overall summary of the scientific evaluation of methadone products for oral use containing povidone
Estonian: Povidooni sisaldavate suukaudsete metadoonpreparaatide teadusliku hindamise üldkokkuvõte
English: The timetable for the implementation of the agreement is set out in Annex V.
Estonian: Koordineerimisrühma seisukoha rakendamise ajakava on V lisas.
English: It was also noted that misuse by injection of methadone product is an inherent risk in the target population with evidence showing an occurrence of injection of methadone for oral use among injecting drug users varying from 5.0% to 79.5% (Winstock et al. 2010, Guichard et al. 2003, Waldvogel et al 2005, Judson G et al. 2010, and Vlahov D et al. 2007) and an underreporting considered to be likely.
Estonian: Samuti märgiti, et metadoonravimi väärkasutamine seda süstides on sihtpopulatsioonis olemuslik risk ja süstivatest narkomaanidest süstivad suukaudset metadooni 5,0% kuni 79,5% (Winstock et al. 2010, Guichard et al. 2003, Waldvogel et al. 2005, Judson G et al. 2010 ja Vlahov D et al. 2007), kusjuures alateatamist peeti tõenäoliseks.
English: On 2nd April 2014, the Norwegian Medicines Agency, NOMA, triggered a referral under Article 107i of Directive 2001/83/EC concerning methadone-containing medicines for oral use containing povidone asking the PRAC to review the benefit-risk balance of all oral methadone medicines containing polyvinylpyrrolidone (more commonly known as povidone or PVP) authorised in the EU and to make a recommendation to the Human Co-ordination Group for Mutual Recognition and Decentralised Procedures (CMDh) on any measures necessary to ensure the safe and effective use, and on whether the marketing authorisation for these products should be maintained, varied, suspended or withdrawn.
Estonian: 2. aprillil 2014 tegi Norra ravimiamet (NOMA) direktiivi 2001/83/EÜ artikli 107i kohase esildise seoses povidooni sisaldavate suukaudsete metadoonravimitega, paludes ravimiohutuse järelevalve riskihindamiskomiteel läbi vaadata kõigi Euroopa Liidus müügiloaga suukaudsete polüvinüülpürrolidooni (povidoon, PVP) sisaldavate metadoonravimite kasulikkuse ja riski tasakaal ning soovitada inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste koordineerimisrühmale ohutu ja efektiivse kasutamise tagamiseks vajalikud meetmed ning otsustada, kas nimetatud ravimite müügiload tuleb säilitada, muuta, peatada või tühistada.
English: In all cases, staining of biological samples supports the conclusion that povidone accumulated in the affected organs.
Estonian: Kõigil juhtumitel toetab bioloogiliste proovide värvimine järeldust, et povidoon kogunes kahjustatud elunditesse.
English: For one of the five patients the bone marrow biopsy showed about 90% histiocytic infiltration characteristic for povidone deposit and only about 5% of bone marrow available for erythropoiesis.
Estonian: Viiest patsiendist ühel esines luuüdi biopsial ligikaudu 90% ulatuses histiotsüütiline infiltratsioon, mis on iseloomulik povidooni kogunemisele, ja erütropoeesiks olemasolevat luuüdi oli ainult ligikaudu 5%.
English: Following parenteral administration, it is generally accepted that low molecular weight povidone (Mw <25 000) is readily excreted by the kidney: the glomerulus can excrete within a few days all povidone of Mw 40 000 or below; the normal glomerulus of healthy human subjects is relatively impermeable to povidone Mw >70 000 (while in humans with nephrotic disease, the permeability for larger molecules was increased); the reticuloendothelial system (RES) retains molecules with a Mw >110,000 (Ravin et al. 1952; Hulme and Hardwicke 1968).
Estonian: Üldiselt arvatakse, et parenteraalselt manustatud väikese molekulmassiga povidoon (Mw <25 000) elimineerub kiiresti neerude kaudu: glomeerulid suudavad elimineerida mõne ööpäeva jooksul kogu povidooni molekulmassiga kuni 40 000; tervete inimeste normaalsed glomeerulid on povidoonile molekulmassiga > 70 000 suhteliselt läbimatud (samas nefrootilise haigusega inimestel oli suuremate molekulide permeaablus suurem); retikuloendoteliaalsüsteemi ei läbi molekulid molekulmassiga üle 110 000 (Ravin et al. 1952; Hulme ja Hardwicke 1968).
English: Supervised administration of every dose was also discussed but this would be difficult to consistently incorporate into daily OST practice and would lead to serious non-compliance.
Estonian: Arutati iga annuse manustamist järelevalve all, kuid seda oleks raske kasutada igapäevases opioid-asendusravi praktikas ning sellega kaasneksid režiimi rasked rikkumised.
English: There is evidence that lower molecular weight povidone (<25,000) is readily excreted but that higher Mw povidone (>110,000) is not, or (>70,000) only partially excreted;
Estonian: On andmeid, et väiksema molekulmassiga povidoon (<25 000) elimineerub kergesti, kuid suurema molekulmassiga povidoon (>110 000) ei elimineeru või (>70 000) elimineerub ainult osaliselt.
English: Pathological fractures were observed in two of the five patients, with deposits of povidone also in the bone tissue.
Estonian: Patoloogilisi luumurde täheldati viiest patsiendist kahel, kellel samuti olid luukoes povidooni ladestused.
English: Methadone is used in the treatment of moderate to severe pain and is also used as maintenance/substitution medication in the management of opioid dependence.
Estonian: Metadooni kasutatakse mõõduka kuni tugeva valu raviks, samuti ka opioidisõltuvuse ravis säilitus-/asendusravimina.
English: It followed the decision of NOMA to suspend the only methadonecontaining oral solution that contains povidone present on the national market, on the basis of reports of serious adverse events in former or current drug abusers in Norway.
Estonian: Sellele eelnes NOMA otsus peatada riigi turul oleva povidooni sisaldava ainsa suukaudse metadoonilahuse müügiluba Norra endistel või praegustel narkomaanidel esinenud raskete kõrvalnähtude teadete alusel.
English: • The PRAC reviewed all available data from published literature, pre-clinical and clinical studies and post-marketing experience on the safety of methadone medicinal products for oral use containing povidone, responses submitted by the marketing authorisation holders (MAHs) in writing and during the oral explanations, the outcome of the ad-hoc expert advisory group meeting as well as stakeholders' submissions in particular with regards to the risks associated with the misuse of the products by injection which is a well-known risk in the target population;
Estonian: • Riskihindamiskomitee vaatas läbi kõik avaldatud kirjandusest, prekliinilistest ja kliinilistest uuringutest ning turustamisjärgsest kogemusest pärit olemasolevad povidooni sisaldavate metadoonpreparaatide ohutusandmed, müügiloa hoidjate kirjalikud ja suulised selgitused, ekspertide ajutise nõuanderühma koosoleku tulemused ning sidusrühmade märkused eelkõige riskide kohta, mis on seotud ravimite väärkasutamisega süstimise teel, mis on sihtpopulatsioonis hästi teada risk.
English: The distribution and elimination of povidone when administered intravenously has been well investigated and studies using radioactive labelled povidone of different molecular weight have demonstrated that clearance of polymers after intravenous administration is dependent on molecular weight.
Estonian: Intravenoosse povidooni jaotumist ja eliminatsiooni on põhjalikult uuritud ja mitmesuguse molekulmassiga radiomärgistatud povidooni uuringud on näidanud, et polümeeride kliirens pärast intravenoosset manustamist oleneb molekulmassist.
English: The inclusion of povidone K90 in oral methadone solutions was initially intended to enhance viscosity and reduce the risk of misuse by injection.
Estonian: Suukaudsetesse metadoonilahustesse povidoon K90 lisamise algne eesmärk oli suurendada viskoossust ja vähendada väärkasutamist süstides.
English: Six kidney biopsies were presented and all demonstrated deposits of povidone in the tubular-interstitial area.
Estonian: Esitati 6 neerubiopsiat, kus kõigis oli povidoon kogunenud tubulaar-interstitsiaalsesse piirkonda.
English: The PRAC noted that all these 15 cases reported “intentional drug misuse”, “product deposit” and “drug administered via inappropriate route” and were assessed by the regional pharmacovigilance centre in Norway as possibly or probably related to the injection of povidone.
Estonian: Ravimiohutuse järelevalve riskihindamiskomitee märkis, et kõigil 15 juhtumil teatati ravimi tahtlikust väärkasutusest, ravimi kogunemisest ja ravimi ebaõigest manustamisviisist ning Norra piirkondlik ravimiohutuse järelevalve keskuse hinnangul olid need võib-olla või tõenäoliselt seotud povidooni süstimisega.
English: For the other eight cases, renal biopsies were lacking, but povidone deposits were detected in biopsies from other tissues.
Estonian: Ülejäänud 8 juhtumil neerubiopsia puudus, kuid povidoon oli kogunenud muudesse kudedesse.
English: High Mw povidone (>110,000) will not be excreted by the kidney and therefore will be retained in the body if repeatedly injected and may lead to serious harm;
Estonian: Suure molekulmassiga povidooni (>110 000) neerude kaudu ei elimineeru, seetõttu jääb see korduva süstimise korral organismi ja võib põhjustada rasket kahju.
English: Although the brand of methadone cannot be confirmed with certainty it is suspected, based on the availability of the product and pattern of usage in Western Norway that the observed serious adverse reactions (e.g. anaemia and bone marrow disorder) were caused by povidone deposition in drug abusers who have misused methadone oral solutions containing povidone K90.
Estonian: Kuigi väärkasutatavat metadoonitoodet ei saa konkreetselt kinnitada, võib oletada Lääne-Norra toote kättesaadavuse ja kasutusmustri põhjal, et täheldatud rasked kõrvalnähud (nt aneemia ja luuüdi kahjustus) põhjustas povidooni ladestumine nende narkomaanide organismis, kes on väärkasutanud povidoon K90-t sisaldavaid suukaudseid metadoonilahuseid.
English: • The PRAC was of the opinion that available pre-clinical and clinical data provide evidence that high molecular weight povidone (>110,000) when injected is likely to be permanently retained in the body, in particular in the bone marrow and bone tissue.
Estonian: • Riskihindamiskomitee oli arvamusel, et olemasolevad prekliinilised ja kliinilised andmed tõendavad, et süstitud suure molekulmassiga povidoon (>110 000) jääb tõenäoliselt püsivalt organismi, eelkõige luuüdisse ja luukoesse.
English: Other methadone products containing povidone concerned by the review are tablets and have lower Mw povidone (e.g. K25, K30, also in lower amount), which is known to be excreted from the kidney and therefore is expected not to be retained in the body.
Estonian: Läbivaatamisega seotud teised povidooni sisaldavad metadoonravimid on tabletid ja need sisaldavad väiksema molekulmassiga povidooni (nt K25, K30, samuti väiksemas koguses), mis elimineerub neerude kaudu ja eeldatavasti ei jää organismi.
English: However, the causality of povidone deposits and bone marrow failure and skeletal fracture has been reasonably demonstrated, and the mechanism of pathophysiology appears to be related to the spatial competition of deposits and bone marrow (Kepes et al 1993; Kuo et al 1997; Dunn et al 1998; Huang et al 2012).
Estonian: Samas on piisavalt tõestatud povidooni ladestuste ja luuüdi kahjustuste ning luumurdude põhjuslik seos, samuti näib patofüsioloogiline mehhanism olevat seotud ladestuste ja luuüdi konkurentsiga ruumi pärast (Képes et al. 1993; Kuo et al. 1997; Dunn et al. 1998; Huang et al. 2012).
English: • The PRAC considered case reports, including fatal cases, in former or current injecting drug users, and noted the serious adverse reactions, the nature of which (including bone marrow adverse effects and pathological fractures) was consistent with the accumulation of povidone and also noted that povidone deposition in organs and tissues had been seen on biopsies.
Estonian: • Riskihindamiskomitee vaatas läbi endistel või praegustel süstivatel narkomaanidel esinenud juhtumite, sh surmajuhtumite teated ja võttis teadmiseks rasked kõrvalnähud, mille iseloom (sh luuüdiga seotud kõrvaltoimed ja patoloogilised luumurrud) viitas povidooni kogunemisele, ning märkis, et biopsial on täheldatud povidooni ladestumist elunditesse ja kudedesse.
English: In most cases, prescription or use of methadone can be confirmed, while some of them also have admitted injecting oral methadone.
Estonian: Enamasti kinnitati metadoonravi määramist ja neist mõnel juhul kinnitati ka suukaudse metadooni süstimist.
English: For five patients, bone destruction and/or bone marrow affection (including anaemia) were reported and findings from biopsies showed accumulation of povidone in the bone marrow.
Estonian: 5 patsiendil teatati luukoe lagunemisest ja/või luuüdi kahjustusest (sh aneemiast) ning biopsial leiti povidooni kogunemine luuüdisse.
English: Flexible-dose methadone maintenance therapy is more clinically effective than no drug therapy in dependent opioid users.
Estonian: Paindliku annusega metadoon-säilitusravi on opioidisõltlastel kliiniliselt efektiivsem kui ravimiteta ravi.
English: High molecular weight povidone therefore accumulates if injected intravenously and povidone deposition in organs and tissues (in particular bone marrow and bone tissue) have been reported in the literature after substantial intravenous administration leading to ‘povidone storage disease' (Kepes et al. 1993; Kuo et al. 1997; Dunn et al. 1998; Huang et al. 2012).
Estonian: Nii koguneb intravenoosselt manustatud suure molekulmassiga povidoon ning kirjanduses on teatatud povidooni ladestumisest elunditesse ja kudedesse (eelkõige luuüdisse ja luukoesse) pärast olulist intravenoosset manustamist, mis tekitab n-ö povidooni ladestumise haiguse (Kepes et al. 1993; Kuo et al. 1997; Dunn et al. 1998; Huang et al. 2012).